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Abstract: 48 
PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the power of big 49 
data in EuRope) is a European network of excellence for big data in prostate cancer, consisting 50 
of 32 private and public stakeholders from 9 countries across Europe. Launched by the 51 
Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme 52 
(BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate 53 
cancer management by unlocking the potential of big data.  54 
The project has identified critical evidence gaps in prostate cancer care, via a detailed 55 
prioritisation exercise including all key stakeholders. By standardising and integrating 56 
existing high quality and multidisciplinary data sources from prostate cancer patients 57 
across different stages of the disease, rich big data will be assembled into a single 58 
innovative data platform for research. Based on a unique set of methodologies, PIONEER 59 
aims at advancing the field of prostate cancer care with particular focus on improving 60 
prostate cancer-related outcomes, health system efficiency by streamlining patient 61 
management, and the quality of health and social care delivered to all prostate cancer 62 
patients and their families. The literature suggests there is underuse of effective 63 
treatments and overuse of ineffective treatment.  For example, androgen deprivation 64 
therapy is sometimes overused in situations where it is not recommended. It is therefore 65 
crucial to identify the best treatment option for the individual patient.  66 
Introduction  67 
 68 
Prostate cancer is the second most common cancer in men by incidence in Europe, with 69 
450,000 new cases diagnosed in 2018. Prostate cancer incidence varies five-fold, with the 70 
highest incidence in Northern and Western Europe, and the lowest in Central and Eastern 71 
Europe. The estimated incidence is highest in Ireland (189.3 per 100,000), whereas Albania 72 
(37 per 100,000) and Romania (47.2 per 100,000) have the lowest incidence (1). In 2018, the 73 
estimated numbers of death of  prostate cancer were 107,300 for Europe (40 European 74 
countries), and 81,500 for 28 members countries of the European Union (1). Total annual 75 
estimated costs for treatment of prostate cancer in the first year following diagnosis is 76 
approximately €117 million in the UK. The figure is two- to three-fold higher in France and 77 
Germany (2). This economic burden associated with prostate cancer  is predicted to 78 
dramatically increase in the coming years due to aging of the population, as around 85% of 79 
all cases of prostate cancer are diagnosed in men over the age of 65 years (1, 3, 4). Despite 80 
these numbers, up to now the level of funding for research is relatively low. For example, in 81 
2018/2019, Cancer Research UK spend £13 million on prostate cancer research out of their 82 
total annual budget of £442 million (5). Therefore, progress made in prostate cancer research 83 
is limited when compared to other major cancer types. (1) For example, mortality statistics of 84 
Cancer Research UK indicate the mortality rate of breast cancer has been steadily declining, 85 
while the prostate cancer mortality rate is still on the rise (5).  86 
 87 
Currently, several critical questions remain unresolved regarding the screening, diagnosis and 88 
treatment of prostate cancer patients, relating to various observations in prostate cancer 89 
epidemiology. First, prostate cancer incidence is variable across different European countries 90 
(37 to 189 per 100,000) (1). The differences in incidence rates of different racial and ethnic 91 
background confirms the involvement of genetic factors. However, environmental factors 92 
may also be implicated as the differences are also observed among men of the same genetic 93 
 
heritage who live in different European countries. Furthermore, inequalities in prostate 94 
cancer survival are also observed across the European Union. Estonia and Latvia have the 95 
highest mortality rates (37.3 per 100,000 and 35.7 per 100,000 respectively), whereas the 96 
mortality rates are the lowest in Spain and Italy (13.2 per 100,000 and 10.7 per 100,000 97 
respectively) (1).  98 
 99 
A variety of risk factors have been scrutinized for prostate cancer, including metabolic 100 
syndrome, obesity, dietary and genetics (6). However, the evidence on risk factors for  101 
prostate cancer remains inconclusive and, importantly, knowledge is lacking regarding patient 102 
characteristics (including molecular characterization) for optimal stratification of patients at 103 
time of diagnosis (6). Several diagnostic and prognostic tests for prostate cancer based upon 104 
molecular biomarkers have emerged, leading to a real challenge how to assess and prioritise 105 
these biomarkers (7). . Moreover, the variable pattern of prostate cancer screening and 106 
Prostate-specific antigen (PSA) testing across countries hinders a meaningful interpretation 107 
of available epidemiologic studies on the main risk factors for prostate cancer. Lithuania is 108 
among the few countries in the world where there is a national prostate cancer screening 109 
programme since 2006 (8). However, prostate cancer screening is considered one of the most 110 
controversial topics in urology, as there are different thresholds for screening frequency and 111 
intervals, and PSA thresholds for biopsy (9). This lack of knowledge means that safe 112 
identification of the candidates for active surveillance is suboptimal and similarly, predicting 113 
which patients will respond better to specific treatments remains difficult (6, 10).  114 
 115 
Meaningful engagement of all key stakeholders is lacking in the processes that define the 116 
most important prostate cancer research questions that urgently need answers. The key 117 
stakeholders include clinicians, pharmaceutical companies, payers, and most importantly 118 
patients (11, 12).  Ultimately, this negatively impacts research findings as the current focus in 119 
prostate cancer management may not be reflective of all different stakeholders.  120 
 121 
Furthermore, knowledge gained in clinical practice (including knowledge informed by real life 122 
data) is not effectively implemented, with variability within and across European countries. 123 
PIONEER will collect data from different prospective and retrospective cohorts; patient 124 
registries; electronic health records; clinically recorded imaging data; patient encounters; 125 
problem lists; medication lists and histories; cancer therapy data; pathology reports, and; 126 
health-related quality of life outcomes. Ineffective implementation of knowledge gained in 127 
clinical practice, may lead to inequality in prostate cancer care, increased risk of short-term 128 
and long-term harms of interventions recommended to patients, as well as excess costs 129 
related to inappropriate management. A recent systematic review has identified geographical 130 
inequalities in the management of prostate cancer, and has highlighted that a better 131 
understanding of the complex social, environmental, and behavioural reasons for these 132 
variations is required (13).   133 
 134 
PIONEER’s vision  135 
 136 
The vision of PIONEER is to transform the management and clinical practice of prostate cancer 137 
 
across all disease stages (Stage I to IV) towards a data-driven and outcome-driven, value-138 
based, and patient-centric health-care system. By applying advanced big data analytics, and 139 
developing a data platform of unparalleled scale, quality and diversity, PIONEER will empower 140 
meaningful improvement in clinical practice, prostate cancer disease-related outcomes, and 141 
health economic outcomes across the European health care landscape. PIONEER aims to bring 142 
together data from various sources including clinical, epidemiology, genetics, and health 143 
economics data. PIONEER will assemble, standardise, harmonise and analyse data from 144 
diverse populations of  prostate cancer patients across different stages of the disease to 145 
provide evidence-based data for improving decision-making by key stakeholders (12). 146 
PIONEER brings together world-leading experts in clinical research, epidemiology, genetics, 147 
urology, big data science, health-economic research, private partners (EFPIA), and health-148 
technology assessment. 149 
  150 
Objectives of PIONEER  151 
 152 
PIONEER has developed 8 individual work packages (WPs): project management and 153 
coordination (WP 1), 4 core research themes (WP 2-5) and 3 cross-cutting support themes 154 
(WP 6-8) (Box 1).  155 
 156 
Approach and methodology 157 
PIONEER will leverage existing valuable clinical  prostate cancer datasets by bringing together 158 
a complementary group of world-leading clinical, epidemiology, genetics, urology, big data 159 
science, health economics, and health technology assessment (HTA) research experts, 160 
together with patient organisations, such as UCAN, Europa Uomo, and European Alliance for 161 
Personalised Medicine (EAPM) (12). The academic part of PIONEER is coordinated by the 162 
European Association of Urology (EAU), and their Guidelines Office, with financial support 163 
from the European Commission through the Innovative Medicines Initiative 2 (IMI2) (14), 164 
complemented by contributions from pharmaceutical industries and private partners of the 165 
European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, the 166 
PIONEER consortium will build upon previous successful IMI projects and the other 167 
components of the BD4BO IMI2 framework (15). (Figure 1) 168 
PIONEER has developed a dual approach, in order to use prostate cancer big data to develop 169 
an outcome-driven, value-based, and patient-centric healthcare system. First, PIONEER will 170 
identify critical evidence gaps in prostate cancer by combining the knowledge of academic 171 
and industry professionals and patients, thus enabling to focus the PIONEER working plan on 172 
a consensus list of research priorities and questions. Then, PIONEER will integrate, analyse, 173 
standardise and harmonise existing data from high quality and multidisciplinary data sources 174 
from  prostate cancer patients across different stages of the disease into a single data 175 
platform (15, 16). To achieve this, PIONEER will use readily available, successful workbench 176 
and tools, such as tranSMART, OHDSI and the SAS open Platform, based on suitable data 177 
harmonisation techniques (OMOP Common Data Model) and advanced analytical methods. 178 
The advanced analytical methods may include machine learning, predictive modelling, multi-179 
omics data integration methods, data visualisations as developed by The Hyve in the IMI1 180 
 
funded project EMIF (the European Medical Information Framework) (17) and by the 181 
European Institute for Systems Biology and Medicine (EISBM (18)) and the Data Science 182 
Institute at Imperial College London (DSI-ICL (19)) in the IMI1 U-BIOPRED (20) and eTRIKS (21) 183 
projects.  184 
Statistical analyses will be facilitated by utilising the KPMG (Klynveld Peat Marwick Goerdeler) 185 
Data Observatory within the DSI-ICL (19), thus enabling the analysis of complex datasets in a 186 
way that uncovers new insights in an immersive and multi-dimensional environment. To 187 
achieve this, the PIONEER statistical team will use the eTRIKS Analytical Environment (21), 188 
OHDSI R package open source (22) and SAS analytics software solutions (23).  189 
Prioritisation of the most important questions in the field of prostate cancer 190 
 191 
The EAU Prostate Cancer Guideline panel and other prostate cancer Key Opinion Leaders 192 
were contacted to identify the most important questions in the field of prostate cancer. Forty-193 
four viable questions were identified. Afterwards, the PIONEER consortium performed a 194 
prioritisation survey among two stakeholder groups: healthcare professionals including 195 
pharmaceutical companies and prostate cancer patients.  196 
 197 
In total, 73 healthcare professionals and 57 patients participated in round one of the surveys. 198 
The results were analysed by calculating the percentage of respondents scoring each question 199 
as not important, important or critically important.. Twelve additional questions were 200 
proposed during the first round. For the second round the patients’ surveys were also 201 
translated into French, German, Italian and Spanish. 49 healthcare professionals and 169 202 
patients (including 53 English; 19 French; 31 German; 53 Italian; 13 Spanish) participated in 203 
round two of the surveys. These 56 questions (44 questions from round one and 12 additional 204 
questions from round two) were then re-ordered according to the highest percentage for 205 
“critically important”. The questions covered all stages of prostate cancer focusing on various 206 
aspects of the condition including screening, diagnosis, risk stratification including the 207 
genomic profile, treatment, and complications of treatment. The detailed results will be 208 
presented in a separate publication, but in meantime are being used to inform PIONEER 209 
consortium, so that the stakeholder groups’ priorities are met in an accountable and 210 
transparent way.  211 
 212 
 213 
WP1: Project management and administration 214 
 215 
PIONEER WP1 ensures the efficient management of the consortium, the progress of the 216 
project towards the planned objectives and deliverables. Implementation of an appropriate 217 
governance structure that allows efficient interaction of the different stakeholders, including 218 
management bodies as well as external scientific and ethical advisory boards, and preparation 219 
of decision-making by the management bodies are crucial aspects of the consortium 220 
management. Given the large number of academic organizations, institutes and private 221 
companies participating in PIONEER (n=32), a major portion of coordination work will be 222 
required to ensure an appropriate flow of information between the different WPs, to facilitate 223 
internal communication between the participants and to coordinate external stakeholder 224 
interactions supporting dissemination and communication (elaborated below in WP7: 225 
 
Dissemination and communication). Furthermore, the linkage of PIONEER with other 226 
programmes of the BD4BO initiative and sustainability of the project’s outcomes beyond the 227 
project duration are integral objectives. 228 
 229 
WP2: Disease understanding and outcome definition 230 
 231 
The aim of WP2 is to develop standardised definitions and measurements of prostate cancer 232 
outcomes and diagnostic, predictive, prognostic, and therapeutic factors (DPPTs) across the different 233 
stages of prostate cancer care, and to consider the opinions of key stakeholders in this process (Box 234 
1: PIONEER Research Objectives).  235 
 236 
To date, many prostate cancer outcomes and DPPTs have been arbitrarily defined and, in the 237 
case of DPPTs, have mainly been investigated in single cohorts. Even in Randomized 238 
controlled trial (RCT) data, heterogeneity of outcome definition and measurement limits 239 
critical appraisal and statistical synthesis of data across sources. This means that analyses 240 
cannot harness the power and precision of all available data. Healthcare providers must 241 
choose from a wide array of diagnostic tools and treatment modalities but due the lack of 242 
consensus on the most important prostate cancer-related outcomes and DPPTs, clinical 243 
practice decision-making is more dauntingly complex than it should be. This contributes to 244 
unacceptable inequalities for prostate cancer patients observed throughout Europe. 245 
Therefore, confirmation of the effectiveness of treatments, or the accuracy of diagnostic 246 
tests, or the utility of predictive biomarkers, can be known with confidence only if the prostate 247 
cancer outcomes and DPPTs become standardised. These standardised definitions will be thus 248 
applied to the large studies contributing data to the PIONEER platform (including data from 249 
patients with different lifestyles and from a range of healthcare systems), in order to identify 250 
outcomes that will allow to discern which patient will benefit most from what treatments, 251 
and to facilitate both drug development and more appropriate patient care.  252 
 253 
The objectives of WP2 are to reach a consensus for each stage of prostate cancer on which 254 
outcomes are the most important for stakeholder groups including healthcare professionals 255 
and patients, how they should be defined and measured, what DPPTs are the most important 256 
for various stakeholders, and how they should be defined and measured.  257 
 258 
First, for the outcomes standardisation work we will update and integrate existing Core 259 
Outcome Set (COS) developed using the COMET and ICHOM processes (24-26). We will 260 
involve both groups in this task and create an up-to-date COS for use within PIONEER and for 261 
future effectiveness trials and clinical audit. We will also survey which DPPTs already exist for 262 
the different stages of prostate cancer care (i.e. screening, diagnostic, staging and treatment 263 
activities) and assess which ones have discriminatory and predictive value. For all reviews we 264 
will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 265 
guidelines (27). These systematic reviews will map current practice and complexities involved 266 
in diagnosis, prognosis and management of men with prostate cancer and overview the 267 
outcomes currently used in research.  268 
 269 
In addition to assessing published literature in our systematic reviews, we will also evaluate 270 
the data collected in the different data resources of PIONEER. This process will result in a 271 
 
structured database of verbatim outcome names, definitions and measures. The outcomes 272 
database will be categorised according to the generic Williamson Clarke taxonomy (28), with 273 
additional prostate cancer specific outcomes and definitions provided (elaborated below in 274 
WP4: Data platform). This will structure and homogenise the available COSs. 275 
 276 
Second, the group will prioritise the identified outcomes and DPPTs for each stage based on 277 
the preferences of different stakeholders involved (i.e. patients and their 278 
family/partner/carer, HTAs, payers/insurance groups, pharmaceutical industry, etc.) using a 279 
modified Delphi consensus-building process as advocated by the COMET initiative (29), and 280 
demonstrated in other prostate cancer specific studies (24, 30).  281 
 282 
The last step will be to identify how to measure the identified COS and DPFs. Currently, 283 
selecting an appropriate outcome measure instrument is challenging given the 284 
comprehensive list of outcome sets WP2 is developing. There is often no single best 285 
measurement defined for the different outcomes so the optimal definition for clinician 286 
reported outcomes (e.g. progression or recurrence) may need to be based on consensus. In 287 
addition, the optimum tools to be used for patient reported outcomes (e.g. urinary function, 288 
quality of life) may rest on the assessment of the tool’s content validity within the target 289 
population, then on other psychometric properties, and the assessment of its feasibility in 290 
research and practice. Ultimately, WP2 aims to develop a pragmatic way to select the 291 
appropriate definitions and measurements.  292 
 293 
The final definitions and measurements will be used as a) the basis of harmonisation of the 294 
outcomes definitions data within PIONEER datasets, and b) the COSs recommended to be 295 
collected as a minimum in future routine data collection, observational studies and clinical 296 
trials. The WP2 has already made substantial progress in standardising and harmonising 297 
outcomes for the interventions of patients with localized and locally advanced prostate 298 
cancer. The PIONEER WP2 first identified all reported outcomes (such as overall survival, 299 
prostate cancer specific survival) from clinical trials of interventions by conducting systematic 300 
reviews. This was followed by expert group consensus meetings with clinicians, patients, 301 
academics and industry representatives, where the identified outcomes from clinical trials 302 
were discussed in detail, to standardize terminology and to recommend core-outcomes set 303 
for localized prostate cancer, that can be used for future research including clinical trials and 304 
studies. The WP2 will develop core-outcomes sets for non-localized prostate cancer as well. 305 
WP2 is currently working on the systematic review protocol of diagnostic and prognostic 306 
factors for all stages of prostate cancer.  307 
 308 
WP3: Data access and sources 309 
 310 
WP3 aims to identify, approach and negotiate appropriate data access agreements with a variety of 311 
potential holders of high-quality, prostate cancer-based datasets across European (and non-312 
European) patient populations (Box 1: PIONEER Research Objectives). WP3 will collect, 313 
standardise and harmonise existing prospective and retrospective data into a single innovative data 314 
platform developed by WP4 (elaborated below in WP4: Data platform). To effectively implement the 315 
WP3 workplan, subgroups were formed within WP3.  316 
 
As part of the initial proposal for the PIONEER consortium, 27 potential data providers were 317 
identified. This number has since grown to over 60 data sources and is expected to continue 318 
to grow as new sources are identified. Potential data contributors include large clinical 319 
practices and medical centres, life sciences companies, data aggregators and 320 
payers/governments.  321 
WP3 will contact biomedical institutes and hospitals holding clinical data, assess their 322 
willingness to participate by obtaining a signed letter of intent and collect information about 323 
the contents of their database(s) by filling in a data contributor Fact Sheet. These Fact Sheets 324 
form the basis for the ‘clinical fingerprint’ (omics data type relevant to  prostate cancer) used 325 
in the EMIF central metadata catalogue developed by The Hyve (WP4) (17). . 326 
Once the data providers’ intent to participate is confirmed, WP3 will begin to negotiate 327 
appropriate Data Access Agreements (DAAs). The DAA templates are based on other IMI 328 
project agreements (i.e. HARMONY (31)) modified by Pinsent Mason Associates (Elaborated 329 
below in WP8: Legal, ethical issues and governance) to suit PIONEER data providers’ needs. 330 
To encourage participation in the PIONEER consortium, the DAAs outline the policies and 331 
procedures under which their data can be accessed and analysed. The DAAs will also include 332 
sections which satisfy country-specific General Data Protection Regulations (GDPRs), data 333 
governance and value propositions tailored to each type of data provider. Suggested value 334 
propositions include authorship, benchmarking, clinical decision-making, transparency 335 
initiatives, technical support and networking opportunities. In exchange for signing the 336 
agreements, data providers are given certain rights and privileges (e.g. the right to propose 337 
research questions, request authorship and opting out of study participation) along with 338 
accepting certain obligations (e.g. a commitment to participate in studies whenever 339 
possible).  340 
Upon signing the DAAs, WP3 will work to convert, harmonise and map the data sets into a 341 
common data model similar to other IMI projects, e.g. EMIF, using a variety of approaches 342 
and software while also maintaining security and consistency. The multiple data sets will be 343 
linked to form the PIONEER platform used for subsequent analyses.  344 
The overall objective of PIONEER is to establish a long-term sustainable research network, 345 
with established policies and procedures for the access and analyses of big data from multiple 346 
sources. WP3 is establishing data management plans to support this sustainability goal that 347 
include options for data providers to continue their participation after the initial funding 348 
phase or withdraw their participation and have their data appropriately decommissioned 349 
from the PIONEER platform.  350 
The biggest challenge is centred around the development of an appropriate data access 351 
framework which will motivate contributors to participate, satisfy GDRP and privacy 352 
regulations while allowing meaningful research collaborations.  353 
WP4: Data platform 354 
 355 
PIONEER WP4 will develop a pan-European data-sharing platform and adopt a two-pronged 356 
approach to address the project needs: a) a platform that can access population-based 357 
 
registry data such as electronic health records, and b) a platform that can handle rich clinical 358 
and omics data for translational analysis by WP5 (elaborated below in WP5: Data analytics). 359 
To achieve this, the project will build upon and use approaches developed in a number of 360 
other IMI projects, such as IMI1 EMIF (17) and IMI1 eTRIKS (21). 361 
 362 
For data integration and analysis of longitudinal  prostate cancer registries, PIONEER will use 363 
the OMOP and OHDSI (22) technology, while for cohort studies that also include omics data 364 
besides deep phenotypic and clinical data, the tranSMART (32) technology will be used (Figure 365 
2). Components from both technologies are still under development.  366 
 367 
WP4 will also use the EMIF catalogue to facilitate centralised storage, management and 368 
sharing of metadata of available prostate cancer data sets. It will provide a list of all the data 369 
sources registered by PIONEER, through a portal and search tools, to enable potential data 370 
users to discover data sources that are most relevant to their research needs, according to a 371 
variety of data source and dataset descriptors, and to support the access request process. 372 
 373 
All data will be harmonised (tranSMART) or standardised (OHDSI-OMOP) before being loaded 374 
in the platform of choice (Box 1: PIONEER Research Objectives). The open-source/available 375 
tools of the IMI1 eTRIKS and IMI1 EMIF projects will be used for harmonisation of data that 376 
are loaded in tranSMART.  377 
 378 
We have envisioned distinct possibilities depending on the nature of the data (centralised vs. 379 
decentralised/federated). In particular, central installation of tranSMART and OMOP-ATLAS 380 
will be chosen for data that may leave the source server or repository, while federated 381 
installations of OMOP-ATLAS will be chosen for data that may not leave the data provider’s 382 
premises.  383 
 384 
We envision that certain federated data sources contain omics information. Currently, there 385 
is no existing platform that support federation of omics data and de novo development would 386 
be beyond the resources and time available. If it becomes a clear need in PIONEER, we have 387 
the choice to either adapt tranSMART to support federated analysis or support omics in the 388 
federated OHDSI platform. Within OHDSI, there is a workgroup aimed at creating support for 389 
analysis of genomics data. 390 
WP5: Data analytics 391 
 392 
PIONEER WP5 is in charge of planning, performing and evaluating the bioinformatics and 393 
systems biology analyses to answer PIONEER research questions.  394 
The team in WP5 will provide a unique toolkit of standard and cutting-edge analytical 395 
methods for the analysis of big data, both from open-source and industry-developed methods 396 
(Box 1: PIONEER Research Objectives). Research questions and core outcome sets have been 397 
 
identified in PIONEER’s survey conducted by WP2. Each of the research questions that 398 
PIONEER will tackle will require different tools and analytic workflows that will be provided 399 
by WP5, through the centralised tranSMART omics platform built by WP4 (Figure 3).  400 
Data analytic workflows in WP5 are built around two main sources: open-source software 401 
(mainly R packages) and commercial software (SAS) (23). Each source has its advantages and 402 
limitations with regards to technical possibilities, user-friendliness, built-in visualisation 403 
capabilities, etc. We envision that the different research questions will require different types 404 
of analytical methods and that different sources will be better suited to meet those 405 
requirements. It is also our expectation that open-source and commercial analytical methods 406 
will feed each other to generate the best possible results for the benefit of the project and 407 
the patients.  408 
PIONEER will achieve its aims by performing the following tasks. First, we will write, evaluate 409 
and circulate data analysis plans and standard operating procedures for data analysis. We will 410 
explore and characterize the demographic and geographic data available to us through the 411 
Data Observatory at the ICL and the visual capabilities of the data analysis platform. In this 412 
process, we will constantly focus attention on the lookout for data error and outliers to seek 413 
the cleanest and most reliable data possible. We will then perform initial analyses by 414 
generating data descriptive statistics to assess the existing predictive models in our dataset 415 
and decide on our benchmarks and internal validation schemes. This will allow us to use 416 
advanced analytical methods with confidence, including but not limited to, multiple omics 417 
data analysis (33), topology data analysis (34), regression modelling (e.g. OPLSDA method 418 
(35)), genetic risks prediction (36), random forest machine learning (37), etc. As the databases 419 
will be a collection from disparate populations and/or database sources, meta-analytic 420 
techniques will be employed to account for between- and within-population variability and 421 
heterogeneity (38, 39). Making sense of the results will be done with the help of knowledge 422 
bases including gProfiler (40), MalaCards (41) and STRING (42). The various predictive models 423 
will be combined into a predictive algorithm for the use of health specialists. We will 424 
demonstrate the improvement of our newly developed models on the benchmarks and 425 
related to the economic burden of  prostate cancer management, and provide user-friendly 426 
scores and evaluating schemes for the physicians and patients benefit [nomograms (43), 427 
against over-diagnosis and over-treatment (44)]. Finally, we will provide recommendations 428 
and guidance documents, disseminated to professional and patient organisations (e.g. EAU, 429 
International Shared Decision-Making Group, Europa Uomo, Movember) in collaboration with 430 
PIONEER WP7 (elaborated below in WP7: Dissemination and communication).  431 
The list of analytical tools that are expected to be of use in PIONEER is still being refined. 432 
However, there will be a heavy need for predictive modelling and machine learning (random 433 
forests, linear modelling, support-vector machines, partial least square regressions). 434 
Visualisation will be provided both at the level of the data platform (either in tranSMART or 435 
OHDSI) directly and with dedicated software included in the SAS suite and in R packages. We 436 
will also monitor and make use of developments in the broader computational systems 437 
biology community as they become available to use. High-performance computing, bringing 438 
big data analytics capabilities when needed to answer PIONEER research questions will be 439 
 
provided through a SPARK infrastructure hosted at the DSI-ICL. Finally, WP5 will make use of 440 
the developments, insights and experience of other research projects through partnerships, 441 
research seminars and the projects members’ experience, either from IMI projects [eTRIKS, 442 
B4B (Brains for Brain), EMIF, parallel BD4BO IMI projects] or from the industry partners’ 443 
internal knowledge and developments.  444 
WP6: HTA regulator 445 
 446 
Through WP6, the PIONEER project will seek to develop, and also validate, a framework for 447 
innovative technologies in prostate cancer using real-world evidence (Box 1: PIONEER 448 
Research Objectives). The latter involves using various health data in real time to help 449 
healthcare professionals make better and quicker decisions. Real-World data has been 450 
defined as “an umbrella term for different types of healthcare data that are not collected in 451 
conventional randomized controlled trials... including patient data, data from clinicians, 452 
hospital data, data from payers and social data” (45).  453 
 454 
Many HTA and payer groups think of real-world evidence as having much potential, but 455 
alignment is still necessary. PIONEER will work with such bodies as well as regulators to 456 
establish minimum evidence requirements while identifying, at an early stage, potential 457 
uncertainties requiring extra data. On top of this, PIONEER will seek to develop reference 458 
models for use in economic evaluations and, as a key objective, will explore whether it can 459 
develop a core set of reference models for different stages of  prostate cancer, or an 460 
overarching modelling framework. This is necessary in order to explore the impact of new 461 
technologies at single points along the pathway, as well as looking at treatment sequences, 462 
as the disease progresses through its multiple stages. 463 
 464 
Effective evaluation of the medical, social, economic and ethical issues of products in a 465 
systematic, transparent, unbiased, robust manner will promote safe, effective, health policies 466 
that are patient-focused and obtain best value - whether at the time of launch or their usage 467 
in real-life circumstances. Adapted tools and openness to evidence produced by methods 468 
other than classic RCTs will be helpful. In the case of adaptive clinical trials, real-world 469 
evidence is crucial. Medical Adaptive Pathways to Patients, known as MAPPs, have been 470 
tested in a European Medicines Agency (EMA) project, and will be used in PIONEER. 471 
 472 
MAPPs are described as a prospectively planned process, starting with the early authorisation 473 
of a medicine in a restricted patient population, followed by iterative phases of evidence 474 
gathering and adaptations of the marketing authorisation to expand access to the medicine 475 
to broader patient populations. The keywords here are the ‘iterative phases of evidence 476 
gathering’, which should use real-world evidence to detect patient responses to new 477 
therapies in a real-time setting. 478 
Meanwhile, many of those mobile applications that we are all now using are essentially 479 
gathering real-world evidence on a daily basis. The more advanced health applications can 480 
provide this while also running simultaneous comparative efficacy trials against existing 481 
therapies. These applications could also solve issues surrounding data interoperability, given 482 
that a data standard is already in place when using iOS or Android platforms. In theory, these 483 
 
real-time datasets could then be sent, for example, as standard XML files to any internet 484 
database in Europe and beyond. 485 
 486 
At the time of writing, several national health databases have been providing an opportunity 487 
to search, identify, and target (pseudo) anonymised patient data. These data can become 488 
available to healthcare professionals offering them integrated real-time updates in the case 489 
of national health records. 490 
The practical benefit could be that such databases may allow a radical reduction in the 491 
development time usually needed in RCTs. Through the stakeholder working group, PIONEER 492 
will propose policy recommendations to develop this area in a structured manner. 493 
WP7: Dissemination and communication 494 
Through WP7, PIONEER will communicate information to the public about the project and its 495 
implementation status by providing comprehensible, educational, and operable information 496 
on PIONEER’s outcomes to all relevant stakeholders including policy-makers as they play a 497 
key role in shaping the research agenda, thus facilitating the implementation and adoption of 498 
PIONEER’s results (Box 1: PIONEER Research Objectives).  499 
WP7 will ensure effective communication within the consortium. Effective internal 500 
communication between consortium partners is of utmost importance. Each partner must be 501 
informed on the progress of the entire project and share common goals and objectives. WP7 502 
will coordinate communication activities with other relevant research and stakeholder 503 
networks and provide for the dissemination of project developed platforms for use by the 504 
wider scientific community. 505 
Optimal and effective dissemination of PIONEER results is essential for the ultimate success 506 
of the project. Our vision is that PIONEER outcomes will influence current (and future) 507 
research agendas, clinical development processes, and reshape current clinical practices 508 
based on up-to-date evidence derived from real-life data. To achieve these objectives, 509 
PIONEER will require the support of all relevant stakeholder groups and to accomplish this, 510 
an effective communication and dissemination strategy has been developed. This strategy 511 
forms the base of all PIONEER communications directions and will be periodically revised to 512 
reflect stakeholders’ feedback relating to the different communication tools and channels. 513 
Primarily, PIONEER dissemination approach is two-fold with the initial phase focused on 514 
increasing general awareness of the project and the second phase geared towards tailored 515 
messages delivered to specific stakeholder audiences.  516 
The PIONEER project website has been developed and was launched during the projects kick-517 
off meeting (14th May 2018), under the registered domain https://prostate-pioneer.eu. In 518 
addition, a PIONEER Twitter account was created in May 2018 (@ProstatePioneer). 519 
Identification of PIONEER target audience is a key step for successful dissemination of the 520 
project outcomes. Successful identification and engagement of all relevant stakeholders 521 
could be a potential challenge. Knowing our target audiences involves knowing the specific 522 
needs of the individual audience and not just the message we want to convey. To overcome 523 
 
communication barriers, it is important to determine the medium through which PIONEER 524 
will communicate with different target audiences and the timing of message delivery. 525 
Information needs to be of good quality, timely, contextually relevant and appropriate to the 526 
intended audience. Furthermore, the early involvement of all relevant stakeholders is a key 527 
enabler: being actively involved in the design and prioritisation of the research questions 528 
addressed throughout the project will help greatly in ensuring ongoing stakeholder 529 
engagement enabling PIONEER to meet its objectives.  530 
WP8: Legal, ethical issues and governance 531 
 532 
In PIONEER WP8, we will be seeking to: (a) map best practices and related issues concerning 533 
governance of big data solutions in healthcare, (b) consolidate learnings to assist the 534 
development of a sustainable governance structure covering issues that may arise from the 535 
use of big data collected from human participants (e.g. use of personal data, patient 536 
confidentiality, patient consent and data ownership), (c) facilitate responsible use of data by 537 
providing advice and guidance to assist all project participants to understand and hence be 538 
better able to comply with relevant legal, regulatory and ethical requirements on privacy and 539 
data protection; (d) coordinate the activities with other IMI2 BD4BO projects to share, test 540 
and evaluate ideas; and (e) provide guidance on dealing with informed consent forms in the 541 
event that the project includes prospective data gathering (Box 1: PIONEER Research 542 
Objectives).  543 
Currently, there are no universally accepted best practices for involvement of patients and 544 
public in such initiatives, and there are still some unanswered questions to be addressed. 545 
Following the existing debate on data protection and the role of patients in clinical research, 546 
PIONEER will establish an Ethical Advisory Board. WP8 will identify the existing best practices 547 
to involve not only co-participants and other stakeholders but also patients and their 548 
organisations in the definition and solution of relevant ethical and legal issues. WP8 will 549 
ensure respecting the privacy rights of the people whose personal data are processed, the 550 
clinical profession duty of confidentiality and the protection of the interests of participants 551 
and researchers (46).  552 
The timing of the PIONEER project coincides with the implementation of the GDPR, which 553 
came into force in May 2018. This is the most significant change in data privacy law over the 554 
past 20 years and creates a challenge to the project in that it allows for individual member 555 
states to choose to apply or to derogate from certain aspects of the GDPR. One of these areas 556 
is the secondary use of healthcare data for research purposes and means that the project 557 
must understand and deal with differing compliance requirements in different member 558 
states. We will be exploring ways to address this, including avoiding the transfer of personal 559 
data by using a federated data model and/or by using anonymisation so as to take the 560 
relevant data outside of the GDPR framework. Thus enabling implementation of a mixed 561 
model in which part of the data, could be handled efficiently and securely in a centralised 562 
data and knowledge management platform (46). 563 
 564 
Planned outcomes of PIONEER 565 
 
 566 
PIONEER will assemble, standardise, harmonise and analyse high-quality big data from diverse 567 
populations of prostate cancer patients across different stages of the disease to provide 568 
evidence-based data for improving decision-making by key stakeholders. This will lead to 569 
meaningful improvement in clinical practice, prostate cancer disease-related outcomes, and 570 
health-economic outcomes across the European healthcare system. Some of the planned 571 
outcomes of PIONEER are listed below (Figure 3): 572 
 573 
 Consensus on the most important prostate cancer outcomes (WP2: Disease 574 
understanding and outcome definition) 575 
 Identification of critical evidence gaps in prostate cancer (as detailed above under: 576 
Prioritisation of the most important questions in the field of prostate cancer 577 
 Standardisation of outcome definition and outcome measures outcomes 578 
 New insights on improved stratification 579 
 Improved standardized care pathways with known better predictable outcomes 580 
 581 
Challenges in PIONEER 582 
The PIONEER project may come across some important challenges. These challenges will not 583 
only be of legal and ethical nature, but we will come across some methodological challenges 584 
as well, such as data quality, data inconsistency, limitation of observational studies, and 585 
analytics issues. The use of big data in medical research and in healthcare systems raises 586 
complex ethical issues, which have significant implications for policy and legal frameworks. 587 
This includes challenges ranging from consent, data privacy, cyber security, to wider social 588 
aspects of the uses to which patient data may be subject. PIONEER has established an 589 
appropriate framework (noting the potential for different applications of certain regulations 590 
between different member states) to ensure that data access, release and linkage, and 591 
governance of combined datasets of the consortium are addressed in a manner compliant 592 
with legal, regulatory and ethical requirements, and that relevant WPs are handling data 593 
accordingly so that patient trust. 594 
 595 
Future directions  596 
 597 
By 2023 the PIONEER project will deliver essential lessons for targeted care and management 598 
of prostate cancer patients. It will house a central data hub supporting a network of 599 
interdisciplinary personnel, to address critical scientific questions.  600 
The success of this journey depends on several key factors, including logistical aspects (public 601 
and private collaboration), data availability, access to data, data quality and harmonisation, 602 
as well as the adoption of a new generation technology into the platform. 603 
The project will highlight the benefits and power of big data to answer important clinical 604 
questions. Transparency and strict legal oversight will guarantee for protection of patients’ 605 
privacy. Our aspiration is to include data from as many countries as possible to represent the 606 
prostate cancer patient population worldwide.  607 
The biggest challenges of PIONEER will likely be to maintain this work and platform accessible 608 
to researchers and clinicians looking for answers to better manage their difficult patient cases. 609 
 
Inclusion of the most appropriate outcome measures as well as relevant economic aspects, 610 
can guide payers to make the right reimbursement decisions.  611 
The potential of PIONEER is immense, with the key for success being a strong foundation. This 612 
unique collaborative structure and outstanding commitment from all participants will 613 
hopefully set a model for other similar big data projects for the benefits of patients, 614 
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Box 1: PIONEER Research Objectives 
 
PIONEER aims to optimise diagnosis and therapeutic management of prostate cancer 
patients across different stages of the disease and across multiple geographies by 
delivering valuable insights from clinical and real-world data and sharing best practices 
(all WPs).  
 To improve disease understanding and deliver a core set of clinically relevant 
standardised prostate cancer-related outcomes (WP2 with WP3, WP4 and WP5). 
 To develop a large and harmonised repository of prostate cancer data that can be 
used to improve evidence-based decision-making for all prostate cancer patients 
and enable a wide variety of data re-use scenarios (WP4 with WP3 and WP5). 
 To provide unique tools for standardisation and analysis of complex prostate cancer 
data sets from a variety of sources, using different data models and different 
terminology, whilst taking into account different layers of information (e.g. 
genomic, transcriptomics, etc.) (WP3 and WP5, with WP4 contributing). 
 To raise awareness, dissemination and widespread implementation of PIONEER 
results (WP6 and WP7 with all WPs). 
 To address the barriers related to data sharing and data protection (WP8 with all 
WPs). 
 
 
